Skip to Content

Invus sells 1,094 shares of Scholar Rock Holding Co. (NASDAQ:SRRK) to Public Equities L.P.

Invus sells 1,094 shares of Scholar Rock Holding Co. (NASDAQ:SRRK) to Public Equities L.P.

The significant shareholder, Public Equities L.P. Invus, sold 1,094 shares of Scholar Rock stock on January 9, 2009. This transaction occurred on Scholar Rock Holding Company’s (NASDAQ: SRRK) behalf. The transaction resulted in a total value of $10,371.12 due to the sale of the shares at an average price of $9.48 per share. After the completion of the transaction, the insider now owns 9,027,950 shares of the company. Based on the current stock price, the value of these shares is approximately $85,584,966. If you follow the link, which will take you to a legal file submitted to the SEC, you will have the opportunity to acquire additional information regarding the transaction. Any transactions and purchases made by major shareholders who control more than 10% of a company’s total shares must be reported to the Securities and Exchange Commission (SEC). This includes both sales and purchases.

In addition, Public Equities L.P. Invus has recently completed one or more transactions that are related to the following:

On Wednesday, the cost of purchasing one share of SRRK increased by $0.21, bringing it to a price of $10.16. The total number of shares of the company’s stock that changed hands was 483,570, which is higher than the typical volume of trading, which is 398,967 shares. Scholar Rock Holding Co. hit an all-time low of $4.32 during its 52-week trading period, while the company reached an all-time high of $22.74 during the same period. The debt-to-equity ratio is 0.17, the quick ratio is 10.60, and the current ratio is 10.60. All three ratios are identical. The stock has had a moving average price of $8.16 for the last 200 trading days, while the moving average price for the last 50 trading days is $8.32.

On November 14, the most recent quarterly earnings report for Scholar Rock, which is publicly traded and can be found under the NASDAQ: SRRK, was made available to the public. The company announced quarterly earnings of $0.55 per share, which came in at $0.13 higher than the consensus estimate of $0.68 per share among industry analysts. Sell-side analysts anticipate that Scholar Rock Holding Co. will experience a loss of $2.37 per share during the current fiscal year.

Recent events have resulted in several stock analysts providing their perspectives on the company’s share price. On September 19, HC Wainwright reaffirmed their “buy” rating on shares of Scholar Rock and set a price objective of $30.00 for the stock. In addition, they provided a price target of $30.00 for the stock. BMO Capital Markets decreased Scholar Rock’s price objective from $43.00 to $32.00 in a research report published on Tuesday, November 15. Despite this modification, the company has continued to assign an “outperform” rating to the stock. JPMorgan Chase & Co. lowered their price target on Scholar Rock from $38.00 to $20.00 and assigned the stock an “overweight” rating in a research report published on Friday, November 18. Five different research experts concluded that buying the stock would benefit the investor. The company is currently regarded as having a consensus rating of “buy,” and the average price objective has been set at $25.67, as indicated by the data found on

In the most recent few months, various institutional investors have adjusted the interests they hold in the company. These investors hold stakes in the company. Rice Hall James & Associates LLC’s ownership of Scholar Rock increased by 2.6% during the second quarter due to the company’s purchase of additional shares. During the most recent quarter, Rice Hall James & Associates LLC increased its stake in the company by 1,203 shares, bringing its total number of shares owned to 47,711, with a market value of $262,000 ($ 47,711 shares). The percentage of Scholar Rock shares that Tudor Investment Corporation and its subsidiaries and affiliates owned increased by 10.5% during the third quarter. Tudor Investment Corporation, along with its affiliates, currently holds a total of 17,327 shares in the company. These shares are currently valued at $120,000 due to the recent purchase of 1,646 additional shares in the company during the most recent quarter. Rhumbline Advisers increased its holdings of Scholar Rock stock by seven point zero percent during the first three months of the year. Rhumbline Advisers has 29,405 shares of the company’s stock, which are currently valued at $379,000, following purchasing of an additional 1,918 shares during the most recent fiscal quarter. Rhumbline Advisers’ holdings in this stock are currently worth $379,000. Denali Advisors LLC successfully gained a 28.6% increase in the proportion of Scholar Rock that the company owned over the third quarter. Denali Advisors LLC has acquired 9,000 shares of the company’s stock, with a combined value of $62,000. This results from the company’s most recent acquisition, which occurred during the most recent quarter and consisted of 2,000 additional shares. Finally, during the first three months of 2018, Point72 Hong Kong Ltd. increased the percentage of Scholar Rock in which it was invested by 1,386.7%. Point72 Hong Kong Ltd now owns 3,171 shares, valued at $41,000, after purchasing an additional 2,958 shares during the most recent quarter. Institutional investors and hedge funds collectively own 91.63% of the total number of shares in the company, making them the company’s largest shareholders.

Scholar Rock Holding Corporation is a biopharmaceutical company that focuses on discovering and developing medications for treating serious illnesses in which protein growth factor signaling plays an important role. Their primary area of research and development is a critical illness. The company’s products include SRK-181, an inhibitor of the activation of latent myostatin that has finished Phase 3 clinical trials for the treatment of spinal muscular atrophy, and apategromab, which is also an inhibitor of the activation of latent myostatin and is being tested for the treatment of cancers that are resistant to checkpoint inhibitor therapies like anti-PD-1 or anti-PD-L1 antibody therapies. Both of these products are being developed to treat spinal muscular atrophy. Both of these products are currently undergoing clinical trials to determine their efficacy in the treatment of


Leave a comment

Your email address will not be published. Required fields are marked *